Therefore, the dual role of C3a/C3aR signaling axis should be considered for the rational designing therapeutic strategies targeting C3a/C3aR in the effective treatment of NAFLD. This evidence concerns the gene C3 and metabolic dysfunction-associated steatotic liver disease.